MS and Demyelinating Disorders

Here's what is coming soon to NeurologyLive.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss the neurologic symptoms associated with COVID-19.

Neurology News Network for the week ending December 26, 2020.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss the resources and tools used to adapt to the COVID-19 pandemic.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss whether the COVID-19 pandemic forced clinicians to change treatment regimens or prescriptions.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to assess how the COVID-19 virus affected the pathology of neurologic disorders.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss how they adopted new methods of care throughout the COVID-19 pandemic.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss how the COVID-19 pandemic has affected telemedicine.

This specialty series is dedicated to assessing the impact COVID-19 has had on the quality of life of patients with neurological disorders and the clinicians who were forced to adapt during this unique era of medical history.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending December 19, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 18, 2020.

Inclusion of measures of other factors that may influence modified cerebral Functional System Score, such as pain, and sleep quality and insomnia, were noted for future research.

Data used from the ENSEMBLE PLUS study showed a comparable frequency of infusion reactions between those who received the 2-hour infusion and the 3.5-hour infusion.

Here's what is coming soon to NeurologyLive.

Stephen Krieger, MD, discusses a new phase 3 trial of nabiximols, which is now recruiting patients with MS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 11, 2020.

No cognitive improvements were observed for exercise versus waitlist groups of cognitively normal patients with MS.

Further results of the 2 phase 3 studies are expected to be completed and presented in detail in first half of 2021, with a BLA submission to follow.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending December 5, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 4, 2020.